NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

$1.71
-0.03 (-1.72%)
(As of 05/17/2024 ET)
Today's Range
$1.66
$1.77
50-Day Range
$1.37
$2.18
52-Week Range
$1.30
$4.89
Volume
117,895 shs
Average Volume
283,517 shs
Market Capitalization
$83.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cue Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
367.8% Upside
$8.00 Price Target
Short Interest
Bearish
10.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
1.38mentions of Cue Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

226th out of 922 stocks

Pharmaceutical Preparations Industry

95th out of 428 stocks

CUE stock logo

About Cue Biopharma Stock (NASDAQ:CUE)

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE Stock Price History

CUE Stock News Headlines

Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
What 4 Analyst Ratings Have To Say About Silence Therapeutics
Cue Biopharma Inc Ordinary Shares
See More Headlines
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/17/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+359.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-50,730,000.00
Net Margins
-711.84%
Pretax Margin
-711.84%

Debt

Sales & Book Value

Annual Sales
$5.49 million
Book Value
$0.62 per share

Miscellaneous

Free Float
43,662,000
Market Cap
$84.63 million
Optionable
Optionable
Beta
1.98
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives


CUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings
or view top-rated stocks.

What is Cue Biopharma's stock price target for 2024?

4 analysts have issued twelve-month price targets for Cue Biopharma's shares. Their CUE share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 367.8% from the stock's current price.
View analysts price targets for CUE
or view top-rated stocks among Wall Street analysts.

How have CUE shares performed in 2024?

Cue Biopharma's stock was trading at $2.64 at the start of the year. Since then, CUE stock has decreased by 35.2% and is now trading at $1.71.
View the best growth stocks for 2024 here
.

When is Cue Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our CUE earnings forecast
.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) announced its earnings results on Thursday, May, 9th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.05. The firm earned $1.72 million during the quarter, compared to analysts' expectations of $0.73 million. Cue Biopharma had a negative trailing twelve-month return on equity of 128.30% and a negative net margin of 711.84%.

What ETF holds Cue Biopharma's stock?

Amplify Treatments, Testing and Advancements ETF holds 10,671 shares of CUE stock, representing 0.22% of its portfolio.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.69%), Monaco Asset Management SAM (0.69%), Wedmont Private Capital (0.08%), Carlson Capital L P (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends
.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CUE) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners